Other languages Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.64 ^USD	-2.96%		+0.61%	+11.56%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	Feb. 09
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025	Jan. 05
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	Nov. 01
Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer	Nov. 01
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Spero Therapeutics Announces Special Protocol Assessment Agreement with Fda for Phase 3 Pivot-Po Trial of Tebipenem Hbr	23-07-31
Spero Therapeutics, Inc. Announces Chief Executive Officer Changes	23-06-14
Spero Therapeutics, Inc. Announces Executives Changes, Effective August 1, 2023	23-06-14
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023	23-02-01
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Spero Therapeutics Closes License Deal With GSK for Investigational Drug for Urinary Tract Infections	22-11-08
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr	22-11-08
Spero Therapeutics to Present Data at IDWeek 2022	22-10-19
USA-Les valeurs à suivre à Wall Street (actualisé)	22-09-23
Sector Update: Health Care Stocks Gain Thursday Afternoon	22-09-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Other languages

Filters